Additionally, FAK inhibitors have been reported to induce cellular senescence in lung cancer cells, potentially by downregulating the expression of enhancer of zeste homolog 2 (EZH2), a protein associated with cancer cell proliferation and survival [45]. Here, EZH2 is linked to lung carcinoma.